1. 1European Medicines Agency. Pandemrix European Public Assessment Report. Summary of Product Characteristics. 2008; Available at http://www.emea.europa.eu/humandocs/PDFs/EPAR/pandemrix/H-832-PI-en.pdf (Accessed 28 May 2009).
2. 2International Federation of Pharmaceutical Manufacturers & Associations Influenza Vaccine Supply International Task Force. Industry provides significant voluntary contributions to global pandemic preparations. 2008; available at http://www.ifpma.org/influenza/content/pdfs/WHO_IGM/2008_11_Industry_Contributions_to_Pandemic_Preparations.pdf (Accessed 28 May 2009).
3. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture;Ehrlich;N Engl J Med,2008
4. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy;Stephenson;JID,2005
5. 5Novartis. Novartis MF59®-adjuvanted vaccine rapidly induces protective antibody levels against diverse strains of avian flu. 2008; Company press release, available at http://www.medicalnewstoday.com/articles/123088.php (Accessed 28 May 2009).